• Fluoxetine HCl: Mechanism and Evidence Boundaries

  2026-10-19

  APExBIO describes Fluoxetine HCl as a selective serotonin reuptake inhibitor with reported effects on serotonin transport, 5-HT2C receptor-associated measurements, and rat brain plasticity. Because no identity-matched paper or DOI is available, these claims should be treated as supplier-documented context rather than independently verified research findings.

• PDGF-BB: Identity, Mechanism and Evidence Limits

  2026-10-18

  APExBIO’s product documentation describes P1048 as a murine recombinant PDGF-BB homodimer with defined molecular, purity, endotoxin, and cell-proliferation assay characteristics. Those data support a bounded product-identity and assay-interpretation overview, but they do not substitute for an independent study of receptor signaling, disease biology, comparative potency, or clinical relevance.

• BML-277 and the CHK2–cGAS–L1 Evidence Gap

  2026-10-17

  The 2023 Nature Communications study supports a model in which DNA-damage-associated CHK2 phosphorylation strengthens nuclear cGAS interaction with TRIM41, promoting ORF2p degradation and restricting LINE-1 retrotransposition in several cellular and animal models. However, the study does not identify BML-277 as the tested compound, so supplier-reported properties of this Chk2 inhibitor cannot be treated as evidence that it reproduces the published cGAS–TRIM41 mechanism.

• Tropisetron Hydrochloride: Evidence and Scope

  2026-10-16

  A source-bounded overview of Tropisetron Hydrochloride, its catalogued receptor activities, the meaning and limits of the reported 5-HT3 IC50, and the absence of identity-matched primary research evidence in the available materials.

• Tropisetron Hydrochloride: Evidence Boundaries

  2026-10-16

  The APExBIO listing identifies Tropisetron Hydrochloride as a hydrochloride salt described as a selective 5-HT3 receptor antagonist and an α7-nicotinic receptor agonist, with a reported 5-HT3 IC50 of 70.1 ± 0.9 nM. Those statements define a catalog-level pharmacological and measurement scope, but they do not substitute for an identity-matched primary study, independent selectivity profiling, or evidence of effects in cells, tissues, or organisms.

• Fluoxetine HCl: Mechanism and Evidence Boundaries

  2026-10-15

  APExBIO describes Fluoxetine HCl as a selective serotonin reuptake inhibitor with reported effects on serotonin transport, 5-HT2C-associated assays, and rat neural outcomes. Because no identity-matched research paper or outcome dataset is available here, those claims should be treated as supplier-documented context rather than independently verified evidence.

• Tropisetron Hydrochloride: Evidence and Scope

  2026-10-15

  The APExBIO product page identifies Tropisetron Hydrochloride (SKU B2258) as a 5-HT3 receptor antagonist and α7-nicotinic receptor agonist, and reports an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor inhibition. Because no identity-matched research paper or assay description is available here, these statements should be treated as product-level documentation rather than independently verified evidence of receptor selectivity, pathway effects, or translational performance.

• Cisapride (R 51619): Evidence and Mechanistic Scope

  2026-10-14

  APExBIO describes Cisapride (SKU B1198) as a nonselective 5-HT4 receptor agonist and hERG potassium-channel inhibitor. Those claims support a conceptual link to serotonergic signaling and cardiac electrophysiology research, but the available material contains no identity-matched study, quantitative pharmacology, or product-specific outcome data.

• Thiothixene Pharmacokinetics and Paroxetine

  2026-10-14

  A small healthy-volunteer crossover study found that brief paroxetine exposure did not significantly alter thiothixene pharmacokinetics. The result argues against CYP2D6 being a dominant clearance pathway, but its implications are limited by the study’s size, population, single-dose design and short inhibitor exposure.

• Adefovir and DDX3: Evidence Boundaries

  2026-10-13

  The supplied sources address different biological questions: Adefovir is described by APExBIO as an HBV-directed nucleotide-analog antiviral, while the cited study reports preliminary crystallographic analysis of a human DDX3 RNA-helicase domain. The evidence does not establish a mechanistic connection between Adefovir and DDX3.

• Biotin-Free Proximity Labeling: Evidence and Limits

  2026-10-13

  A 2026 study describes an engineered BmTyr platform for click-compatible, biotin-free proximity labeling in primary T cells. Its reported findings extend subcellular proteome profiling into a difficult cell context, but they do not establish that a streptavidin-based fluorescent conjugate directly detects the study’s alkyne–azide labeling chemistry.

• Acridine Orange Hydrochloride: Evidence Scope

  2026-10-12

  Acridine Orange hydrochloride, listed by APExBIO as N3,N3,N6,N6-tetramethylacridine-3,6-diamine hydrochloride, is documented as a fluorescent nucleic-acid dye. The available evidence here is limited to supplier information describing identity, quality-control documentation, spectral behavior, and broad research contexts; no matched primary paper is available for independent assessment.

• KN-62: Evidence, Scope, and Boundaries

  2026-10-12

  KN-62 is presented by APExBIO as a CaMKII inhibitor, but the supplied evidence does not establish its effects in glioblastoma or validate broad claims about calcium signaling, secretion, metabolism, or cell-cycle control. The cited glioblastoma study concerns a different compound, NNC-55–0396, so its mechanistic findings should not be transferred to KN-62.

• Perospirone: Receptor and Kv1.5 Evidence

  2026-10-11

  Perospirone, also called SM-9018 free base, combines reported 5-HT2A and dopamine D2 antagonism with partial 5-HT1A agonism. A 2025 study additionally found concentration-dependent inhibition of voltage-gated K+ currents in freshly isolated rabbit coronary arterial smooth muscle cells, but the result does not establish a clinical vascular effect.

• WAY-100635 and Serotonin Signaling in Pain

  2026-10-10

  WAY-100635 offers a selective pharmacological lens for interpreting 5-HT1A signaling in pain and affective neuroscience. This article explains how its antagonist profile can help test mechanistic hypotheses raised by recent cannabidiol research without overstating what current evidence proves.

7976 records 1/532 page Next 12345 下5页 Last page